In recent years, molecular targeted therapies in oncology have been a big hit. It is due to the emergence of targeted therapies that have benefited the survival of many tumor patients. For example, breast cancer, lung cancer, colorectal cancer, kidney cancer, melanoma, leukemia, lymphoma, gastrointestinal mesenchymal tumor, etc. Many new molecular targeted drugs are introduced every year. Every year, many new molecular targeted drugs are introduced and new indications are added to the existing molecular targeted drugs. The mechanism of action of commonly used targeted drugs is summarized as follows: 1, signal transduction: TKase inhibitors – gefitinib, erlotinib, imatinib, dasatinib, nilotinib, sorafenib, sunitinib, vandetanib, ectoin 2, neovascularization: small molecule compounds – Endo; monoclonal antibodies -bevacizumab 3, regulatory genes: trastuzumab 4, EGFR receptors: small molecule compounds-TKIs; monoclonal antibodies-cetuximab, nitrozumab, panitumumab 5, surface receptors: rituximab Target: HER2 Tumor type: breast cancer Indications. HER2-positive metastatic breast cancer without prior anti-HER2 therapy or chemotherapy, in combination with trastuzumab and docetaxel 5, T-DM1 (Kadcyla) Target: HER2 Tumor type: breast cancer Indication: HER2-positive metastatic breast cancer, previously treated with Herceptin and paclitaxel chemotherapy. 6. bevacizumab (Avastin) Target: VEGF Tumor type: colorectal cancer, non-small cell lung cancer, malignant glioma, renal cancer Indications: Metastatic colorectal cancer. First- or second-line therapy in combination with intravenous infusion of 5-FU-based chemotherapy; second-line therapy in combination with fluorouracil-based chemotherapy after progression on first-line bevacizumab-containing regimens. Advanced non-squamous non-small cell lung cancer. Combination carboplatin and paclitaxel for previously untreated patients with advanced Metastatic kidney cancer, in combination with IFN-alpha. Malignant glioma, use at disease progression after initial therapy, single agent use.